强生Johnson & Johnson (JNJ) 2002年年度报告「NYSE」.pdf

1、2002Annual ReportDescription of the CompanyJohnson&Johnson has$36.3 billion in salesand is the worlds most comprehensive and broadlybased manufacturer of health care products,as well as a provider of related services,for theconsumer,pharmaceutical,and medical devicesand diagnostics markets.Johnson&J

2、ohnsonhas approximately 108,300 employees and morethan 200 operating companies in 54 countriesaround the world,selling products in more than175 countries.%ChangeContents1Letter to Shareholders 5Editorial Section 24Board of Directors 24Committees of the Board 26Corporate Officers and Company Group Ch

3、airmen 27Corporate Governance and Managements Responsibility28Managements Discussion and Analysis38Consolidated Financial Statements 42Notes to Consolidated Financial Statements 56Independent Auditors Report 57Segments of Business and Geographic Areas 58Summary of Operations and Statistical Data 199

4、2-2002 59Principal Global Affiliates 63Worldwide Family of Companies 67Corporate and Shareholder/Investor Information On the CoverAt the Malvern,Pennsylvania,facility of Centocor,Inc.,the new monoclonal antibody manufacturingfacility where Joyce Salpan,manufacturingassociate,foreground,and Chaley La

5、rson,seniorsupervisor,work will help the company double itscapacity to produce REMICADE(infliximab)forrheumatoid arthritis and Crohns disease patients.ThreeYears in BriefWorldwide(Dollars in Millions Except Per Share Figures)20022001200020022001Sales to customers$36,298$32,317 29,172 12.3 10.8 Net e

6、arnings*6,597 5,668 4,953 16.4 14.4 Cash dividends paid2,381 2,047 1,724 16.3 18.7 Shareholders equity22,697 24,233 20,395(6.3)18.8 Percent return on averageshareholders equity28.1 25.4 26.5 Per ShareNet earnings-basic2.201.87 1.65 17.6 13.3-diluted2.161.84 1.61 17.4 14.3 Cash dividends paid0.7950.7